PPIDT00332
Drug Information
| Name | Tralokinumab |
|---|---|
| Sequence | QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGLSWVRQAPGQGLEWMGWISANNGDTNYGQEFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDSSSSWARWFFDLWGRGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK |
| DrugBank_ID | DB12169 |
| Type | biotech |
| Indication | Tralokinumab is indicated in Canada, the US, and the EU for the treatment of moderate-to-severe atopic dermatitis in patients who are candidates for systemic therapy and are inadequately controlled with topical interventions.[L39282,L39558,L39287] In Canada, tralokinumab is only approved for adults, while in the US and Europe, it is approved for use in patients 12 years of age and older.[L39287,L39558,L39282] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Subcutaneous |
150 mg/1mL
|
| Injection, solution | Subcutaneous |
300 mg/2mL
|
| Injection, solution | Subcutaneous |
150 MG
|
| Injection, solution | Subcutaneous |
300 mg
|
| Solution | Subcutaneous |
150 mg / mL
|
| Solution | Subcutaneous |
300 mg / 2 mL
|